Efficacy and safety of mifepristone as a sole induction agent in intrauterine fetal demise in scarred and unscarred uterus

Divya Mangla; Surbhi Verma; Neha Khan; S. P. Singh

doi:10.18203/2320-1770.ijrcog20261279

Authors

Divya Mangla Department of Obstetrics and Gynecology, Shahe Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India
Surbhi Verma Department of Obstetrics and Gynecology, Shahe Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India
Neha Khan Department of Obstetrics and Gynecology, Shahe Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India
S. P. Singh Department of Obstetrics and Gynecology, Shahe Shaheed Hasan Khan Mewati Government Medical College, Nuh, Haryana, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20261279

Keywords:

Mifepristone, Induction of labour, Intrauterine fetal demise, Scarred uterus, Second trimester termination

Abstract

Background: Termination of pregnancy in the second and third trimester due to intrauterine fetal demise (IUFD) or lethal fetal anomalies requires safe and effective methods of induction of labour. Mifepristone, an antiprogestin, has been used for cervical ripening and labour induction. This study aimed to evaluate the efficacy and safety of mifepristone as a sole agent for induction of labour in pregnancies beyond 20 weeks of gestation in women with both scarred and unscarred uterus.

Methods: This prospective clinical study was conducted in the Department of Obstetrics and Gynaecology at Shaheed Hasan Khan Mewati Government Medical College, Nalhar, Haryana over a period of one year after approval from the institutional ethics committee. A total of 54 antenatal women with gestational age >20 weeks requiring termination due to intrauterine fetal demise, lethal fetal malformation or PPROM were included. Tablet mifepristone 200 mg was administered orally at 12-hour intervals for a maximum of three doses. Patients were monitored for onset of labour and delivery. Primary outcome measured was successful vaginal delivery following induction with mifepristone alone. Secondary outcomes included induction-delivery interval, requirement of additional uterotonics and maternal complications.

Results: Most patients belonged to the age group of 18–24 years (48.14%), and the majority were multiparous. Scarred uterus was present in 24.07% of cases while 75.93% had unscarred uterus. A total of 87.04% of women delivered within 72 hours of the first dose of mifepristone without the need for additional uterotonics. Additional induction methods such as misoprostol or intracervical Foley’s catheter were required in 12.96% of cases. The majority of patients (59.25%) delivered between 24–72 hours following the first dose of mifepristone. No cases of uterine rupture, scar dehiscence, retained products of conception, or requirement of caesarean section or hysterotomy were observed.

Conclusions: Mifepristone is an effective and safe agent for induction of labour in pregnancies beyond 20 weeks with intrauterine fetal demise or lethal fetal anomalies in both scarred and unscarred uterus. Its use is associated with a high rate of successful vaginal delivery with minimal maternal complications.

References

Government of India. Health Management Information System 2021-22 report. New Delhi: Ministry of Health and Family Welfare. 2022. Available at: https://mohfw.gov.in/. Accessed on 13 February 2026.

Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1993;45:384-409.

Cheng L, Kelly RW, Thong KJ, Hume R, Baird DT. The effects of mifepristone (RU486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum Reprod. 1993;8(5):705-9.

Cheng L, Kelly RW, Thong KJ, Hume R, Baird DT. The effect of mifepristone (RU486) on the immunohistochemical distribution of prostaglandin E and its metabolite in decidual and chorionic tissue in early pregnancy. J Clin Endocrinol Metab. 1993;77(4):873-7.

Cabrol D, Bouvier D'Yvoire M, Mermet E, Cedard L, Sureau C, Baulieu EE. Induction of labor with mifepristone (RU 486) after intrauterine fetal death. Lancet. 1985;2(8468):1019-20.

Cabrol D, Dubois C, Cronje H, Gonnet JM, Guillot M, Maria B. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. Am J Obstet Gynecol. 1990;163(2):540-2.

Frydman R, Lelaidier C, Baton-Saint-Mleux C, Fernandez H, Vial M, Bourget P. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol. 1992;80(6):972-5.

Lelaidier C, Baton C, Benifla JL, Fernandez H, Bourget P, Frydman R. Mifepristone for labour induction after previous caesarean section. Br J Obstet Gynaecol. 1994;101(6):501-3.

Hapangama D, Neilson JP. Mifepristone for induction of labour. Cochrane Database Syst Rev. 2009;(3):CD002865.

Athawale R, Acharya N, Samal S, Hariharan C. Effect of mifepristone in cervical ripening for induction of labour. Int J Reprod Contracept Obstet Gynecol. 2013;2(1):35-8.

Yelikar K, Deshpande S, Deshpande R, Lone D. Safety and efficacy of oral mifepristone in pre-induction cervical ripening and induction of labour in prolonged pregnancy. J Obstet Gynaecol India. 2015;65(4):221-5.

Baev OR, Rumyantseva VP, Tysyachnyu OV, Kozlova OA, Sukhikh GT. Outcomes of labour induction in pregnant women with unfavourable cervix: mifepristone versus dinoprostone. Eur J Obstet Gynecol Reprod Biol. 2017;217:144-9.

Väyrynen W, Heikinheimo O, Mäkikallio K, Nuutila M. Misoprostol only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal death. Acta Obstet Gynecol Scand. 2007;86(6):701-5.

Ahuja N, Dahiya P. A comparative study of mifepristone alone versus mifepristone and misoprostol for induction of labor in intrauterine fetal death. Indian J Obstet Gynecol Res. 2016;3(4):348-51.

Srivastava S, Sarkar R, Bhadkaria S, Sharma P. Comparative study on the efficacy of mifepristone versus mifepristone and misoprostol in the induction of labor in cases of intrauterine fetal demise. Int J Reprod Contracept Obstet Gynecol. 2024;13(3):611-6.

Stibbe KJM, De Weerd S. Induction of delivery by mifepristone and misoprostol in termination of pregnancy and intrauterine fetal death: second- and third-trimester induction of labor. Arch Gynecol Obstet. 2012;286(3):795-6.

Arora R, Patel PB, Dabral A, Sachdeva M, Arya P. Use of mifepristone for termination of intrauterine fetal demise in previously scarred uterus in later half of pregnancy (>20 weeks). Int J Reprod Contracept Obstet Gynecol. 2018;7(7):2668-71.

Padayachi T, Moodley J, Norman RJ. Termination of pregnancy with mifepristone after intrauterine fetal death. S Afr Med J. 1989;75:540-2.